Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A study entitled, “Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes,” to be published in the December 2023 issue of The American Journal of Managed Care® (AJMC®), was referenced in articles from US News & World Report, Medpage Today, Medical News Today, Healio, HealthDay, and Medical Economics®. The study found that approximately 40% of patients with type 2 diabetes discontinued their second-line therapies within a year.
An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Health Insurance Markets Remain Highly Concentrated in the Majority of US,” covered a report from the American Medical Association that found the market for health insurance, both commercial and Medicare Advantage, became more concentrated from 2014 to 2022.
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen